BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC |
| October 05, 2018 | October 2018 Bond Updates |
|
BERGEN, Norway, October 5, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the Company's selective AXL inhibitor bemcentinib in combination with MSD's anti-PD-1 therapy,... |
| View more at: https://www.prnewswire.com:443/news-releases/bergenbio-enters-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc-300725087.html |
| Related News |
|